PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
PTC Therapeutics, Inc.NASDAQ: PTCT
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $7.14M (cash outflow) rose 82.1% year over year, behind the +1172.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 428.0% from the prior quarter. Over 3 fiscal years it compounded at +25.3% a year.
Context
- Capital expenditures amounted to 17.3% of revenue in FY2025, up 8.1 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +82.1% toward the trailing-twelve-month pace of +1172.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (300.01M) USD
- Year-over-year change
- -304.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (300.01M) | -304.1% |
| FY2024 | 2024-12-31 | (74.25M) | +38.4% |
| FY2023 | 2023-12-31 | (120.62M) | +20.9% |
| FY2022 | 2022-12-31 | (152.46M) | -78.7% |
| FY2021 | 2021-12-31 | (85.33M) | — |
Capital Expenditures vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 capital expenditures of $302.05M is the 2nd largest of the 11 companies compared; the peer median is $17.94M.
- Its year-over-year change of +1172.9% is the 2nd highest of 11, against a peer median of +67.6%.
- Capital expenditures amounts to 29.9% of revenue for PTCT, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $78.07B | +88701.7% | -5.2% | 7.6% | |
| LTM Jun 2026 | $302.05M | +1172.9% | +25.3% | 29.9% | |
| LTM Sep 2026 | $71.85M | +29.1% | +36.8% | 7.5% | |
| LTM Mar 2026 | $69.14M | -54.0% | +46.8% | 3.2% | |
| LTM Jun 2026 | $21.4M | +803.5% | -14.5% | — | |
| LTM Mar 2026 | $21.33M | +958.6% | -4.7% | — | |
| LTM Jun 2026 | $14.56M | +46.2% | -39.1% | 3.3% | |
| LTM Mar 2026 | $9.32M | +140.4% | -65.5% | 1.4% | |
| LTM Jun 2026 | $5.52M | -52.7% | -44.2% | 0.8% | |
| LTM Mar 2026 | $1.19M | +88.9% | -27.4% | — | |
| LTM Mar 2026 | $981.99K | +43.1% | -19.2% | 1.4% | |
| Peer median (excluding PTCT) | $17.94M | +67.6% | -16.8% | 3.2% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| Deferred Income Tax | 377K | (34.28M) | (46.93M) | (55.91M) | (3K) |
| Stock-Based Compensation | 103.51M | 110.33M | 131.21M | 74.62M | 74.55M |
| Change in Working Capital | (23.79M) | (85.34M) | (4M) | 102.54M | (47.88M) |
| Accounts Receivables | (44.99M) | (48.47M) | (1.54M) | 1.73M | (10.15M) |
| Inventory | 1.8M | (6.67M) | (8.18M) | 6.16M | (53.9M) |
| Accounts Payables | 23.41M | 27.54M | 0 | 0 | 0 |
| Other Working Capital | (4.01M) | (57.74M) | 5.72M | 94.65M | 16.17M |
| Other Non-Cash Items | 128.33M | 82.81M | 151.32M | 58.7M | (36.93M) |
| Operating Cash Flow | (251.33M) | (356.65M) | (158.42M) | (107.69M) | 711.2M |
| Capital Expenditures | (85.33M) | (152.46M) | (120.62M) | (74.25M) | (300.01M) |
| Acquisitions (Net) | 57.12M | 128.44M | 0 | 0 | 0 |
| Purchases of Investments | (543.27M) | (75.55M) | (212.48M) | (667.36M) | (1.42B) |
| Sales of Investments | 847.78M | 518.19M | 156.37M | 607.74M | 855.12M |
| Other Investing Activities | (57.12M) | (128.44M) | (92.18M) | 110.31M | (291.08M) |
| Investing Cash Flow | 219.18M | 290.18M | (176.74M) | 44.18M | (861.98M) |
| Debt Repayment | (2.22M) | 148.72M | (301.38M) | (1.49M) | (1.61M) |
| Common Stock Issued | 23.1M | 50M | 0 | 0 | 99.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (30.77M) | 947.78M | 257.36M | 233.66M |
| Financing Cash Flow | 20.88M | 167.95M | 646.4M | 255.87M | 331.09M |
| Effect of Forex Changes | (7.82M) | (2.77M) | 3.11M | (7.33M) | 22.71M |
| Net Change in Cash | (19.09M) | 98.71M | 314.36M | 185.03M | 203.02M |
| Free Cash Flow | (336.66M) | (509.11M) | (279.04M) | (181.94M) | 411.18M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.